154 related articles for article (PubMed ID: 26970404)
1. Pharmacokinetic and Pharmacodynamic Modeling Analysis of Intravenous Esomeprazole in Healthy Volunteers.
Liu D; Yang H; Jiang J; Nagy P; Shen K; Qian J; Hu P
J Clin Pharmacol; 2016 Jul; 56(7):816-26. PubMed ID: 26970404
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics, pharmacodynamics, and safety of esomeprazole injection/infusion in healthy Chinese volunteers: a five-way crossover study.
Yang H; Li J; Zhao Q; Li J; Shen K; Yang X; Jiang J; Hu P; Qian J
J Gastroenterol Hepatol; 2013 Dec; 28(12):1823-8. PubMed ID: 23800161
[TBL] [Abstract][Full Text] [Related]
3. A comparison of the acid-inhibitory effects of esomeprazole and pantoprazole in relation to pharmacokinetics and CYP2C19 polymorphism.
Hunfeld NG; Touw DJ; Mathot RA; Mulder PG; VAN Schaik RH; Kuipers EJ; Kooiman JC; Geus WP
Aliment Pharmacol Ther; 2010 Jan; 31(1):150-9. PubMed ID: 19785625
[TBL] [Abstract][Full Text] [Related]
4. A novel K+ competitive acid blocker, YH4808, sustains inhibition of gastric acid secretion with a faster onset than esomeprazole: randomised clinical study in healthy volunteers.
Yi S; Lee H; Jang SB; Byun HM; Yoon SH; Cho JY; Jang IJ; Yu KS
Aliment Pharmacol Ther; 2017 Aug; 46(3):337-346. PubMed ID: 28543183
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and Acid Suppressant Efficacy of Esomeprazole after Intravenous, Oral, and Subcutaneous Administration to Healthy Beagle Dogs.
Hwang JH; Jeong JW; Song GH; Koo TS; Seo KW
J Vet Intern Med; 2017 May; 31(3):743-750. PubMed ID: 28407418
[TBL] [Abstract][Full Text] [Related]
6. The pharmacokinetics, pharmacodynamics and safety of oral doses of ilaprazole 10, 20 and 40 mg and esomeprazole 40 mg in healthy subjects: a randomised, open-label crossover study.
Shin JS; Lee JY; Cho KH; Park HL; Kukulka M; Wu JT; Kim DY; Park SH
Aliment Pharmacol Ther; 2014 Sep; 40(5):548-61. PubMed ID: 25041486
[TBL] [Abstract][Full Text] [Related]
7. Effect of intravenous application of esomeprazole 40 mg versus pantoprazole 40 mg on 24-hour intragastric pH in healthy adults.
Hartmann D; Eickhoff A; Damian U; Riemann JF; Schilling D
Eur J Gastroenterol Hepatol; 2007 Feb; 19(2):133-7. PubMed ID: 17272998
[TBL] [Abstract][Full Text] [Related]
8. Intravenous esomeprazole (40 mg and 20 mg) inhibits gastric acid secretion as effectively as oral esomeprazole: results of two randomized clinical studies.
Wilder-Smith CH; Bondarov P; Lundgren M; Niazi M; Röhss K; Ahlbom H; Nyman L
Eur J Gastroenterol Hepatol; 2005 Feb; 17(2):191-7. PubMed ID: 15674097
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and pharmacodynamics of intravenous esomeprazole at 2 different dosages in dogs.
Seo DH; Lee JB; Hwang JH; Jeong JW; Song GH; Koo TS; Seo KW
J Vet Intern Med; 2019 Mar; 33(2):531-535. PubMed ID: 30548689
[TBL] [Abstract][Full Text] [Related]
10. First-line eradication for Helicobacter pylori-positive gastritis by esomeprazole-based triple therapy is influenced by CYP2C19 genotype.
Saito Y; Serizawa H; Kato Y; Nakano M; Nakamura M; Saito H; Suzuki H; Kanai T
World J Gastroenterol; 2015 Dec; 21(48):13548-54. PubMed ID: 26730167
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the pharmacokinetics and tolerability of HCP1004 (a fixed-dose combination of naproxen and esomeprazole strontium) and VIMOVO® (a marketed fixed-dose combination of naproxen and esomeprazole magnesium) in healthy volunteers.
Choi Y; Han H; Shin D; Lim KS; Yu KS
Drug Des Devel Ther; 2015; 9():4127-35. PubMed ID: 26257511
[TBL] [Abstract][Full Text] [Related]
12. Esomeprazole 40 mg twice daily in triple therapy and the efficacy of Helicobacter pylori eradication related to CYP2C19 metabolism.
Sheu BS; Kao AW; Cheng HC; Hunag SF; Chen TW; Lu CC; Wu JJ
Aliment Pharmacol Ther; 2005 Feb; 21(3):283-8. PubMed ID: 15691303
[TBL] [Abstract][Full Text] [Related]
13. A single dose of intravenous esomeprazole decreases gastric secretion in healthy volunteers.
Nichita C; Abdou AE; Maerten P; Herranz M; Mouret N; Thalmann C; Michetti PF; Dorta G
Aliment Pharmacol Ther; 2009 Nov; 30(10):1022-9. PubMed ID: 19702644
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and Pharmacodynamics of Esomeprazole/Sodium Bicarbonate Immediate-Release Capsules in Healthy Chinese Volunteers: A Cross-Over, Randomized Controlled Trial.
Jing S; Zhu Y; Liu W; Yang K; Hu L; Deng D; Lu C; Lin Y
Adv Ther; 2021 Mar; 38(3):1660-1676. PubMed ID: 33575950
[TBL] [Abstract][Full Text] [Related]
15. Potent Gastric Acid Inhibition Over 24 Hours by 4-Times Daily Dosing of Esomeprazole 20 mg.
Sahara S; Sugimoto M; Uotani T; Ichikawa H; Yamade M; Kagami T; Hamaya Y; Iwaizumi M; Osawa S; Sugimoto K; Miyajima H; Furuta T
Digestion; 2015; 91(4):277-85. PubMed ID: 25924819
[TBL] [Abstract][Full Text] [Related]
16. Early effects of oral administration of esomeprazole and omeprazole on the intragastric pH.
Iida H; Inamori M; Okuno K; Sekino Y; Sakai E; Okubo H; Higurashi T; Endo H; Hosono K; Yoneda M; Koide T; Takahashi H; Goto A; Kubota K; Saito S; Maeda S; Nakajima A; Gotoh E
Hepatogastroenterology; 2015; 62(138):493-6. PubMed ID: 25916088
[TBL] [Abstract][Full Text] [Related]
17. Esomeprazole 40 mg provides improved intragastric acid control as compared with lansoprazole 30 mg and rabeprazole 20 mg in healthy volunteers.
Wilder-Smith CH; Röhss K; Nilsson-Pieschl C; Junghard O; Nyman L
Digestion; 2003; 68(4):184-8. PubMed ID: 14691345
[TBL] [Abstract][Full Text] [Related]
18. The effect of the area under the plasma concentration vs time curve and the maximum plasma concentration of esomeprazole on intragastric pH.
Junghard O; Hassan-Alin M; Hasselgren G
Eur J Clin Pharmacol; 2002 Oct; 58(7):453-8. PubMed ID: 12389067
[TBL] [Abstract][Full Text] [Related]
19. An open-label, parallel, multiple-dose study comparing the pharmacokinetics and gastric acid suppression of rabeprazole extended-release with esomeprazole 40 mg and rabeprazole delayed-release 20 mg in healthy volunteers.
Morelli G; Chen H; Rossiter G; Rege B; Lu Y
Aliment Pharmacol Ther; 2011 Apr; 33(7):845-54. PubMed ID: 21272047
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetic analysis of esomeprazole in Japanese subjects with various CYP2C19 phenotypes.
Nagase M; Shimada H; Nii M; Ueda S; Higashimori M; Ichikawa K; Zhang L; Zhou L; Chen Y; Zhou D; Dunyak J; Al-Huniti N
J Clin Pharm Ther; 2020 Oct; 45(5):1030-1038. PubMed ID: 32227647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]